ArticlePloS one2016
Benefits of Bifidobacterium breve M-16V Supplementation in Preterm Neonates - A Retrospective Cohort Study.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Prophylactic Probiotic Supplementation for Preterm Neonates-A Systematic Review and Meta-Analysis of Nonrandomized Studies.Advances in nutrition (Bethesda, Md.) · 2021Pooled it
- Global incidence of Necrotizing Enterocolitis: a systematic review and Meta-analysis.BMC pediatrics · 2020Pooled it
- Pooled it
- Trial
- Early Probiotic Supplementation of Healthy Term Infants withNutrients · 2023Trial
- Effect of single versus multistrain probiotic in extremely preterm infants: a randomised trial.BMJ open gastroenterology · 2022Trial
- Composition of Coloured Gastric Residuals in Extremely Preterm Infants-A Nested Prospective Observational Study.Nutrients · 2020Trial
- Effects of Bifidobacterium infantis M-63 on gut environment and bowel function during weaning: RCT.Pediatric research · 2026Article
- A Review of Probiotic Interventions for Necrotizing Enterocolitis and Sepsis in Preterm Infants.International journal of molecular sciences · 2026Review
- Monensin phase-out in Norwegian turkey production decreasesMicrobial genomics · 2025Article
- Modulation of Bifidobacterium by HD5 during weaning is associated with high abundance in later life.Communications medicine · 2025Article
- Incidence of probiotic sepsis and morbidity risk in premature infants: a meta-analysis.Pediatric research · 2025Article
- Article
- Role ofCurrent developments in nutrition · 2023Review
- Infant microbiome cultivation and metagenomic analysis reveal Bifidobacterium 2'-fucosyllactose utilization can be facilitated by coexisting species.Nature communications · 2023Article
- Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.Nature microbiology · 2023Article
- Study of the biosynthesis and functionality of polyphosphate in Bifidobacterium longum KABP042.Scientific reports · 2023Article
- Review
- Strain-specific alterations in gut microbiome and host immune responses elicited by tolerogenic Bifidobacterium pseudolongum.Scientific reports · 2023Article
- Probiotic supplementation for neonates with congenital gastrointestinal surgical conditions: guidelines for future research.Pediatric research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystematic reviews of randomised controlled trials report that probiotics reduce the risk of necrotising enterocolitis (NEC) in preterm neonates.
aimTo determine whether routine probiotic supplementation (RPS) to preterm neonates would reduce the incidence of NEC.
methodsThe incidence of NEC ≥ Stage II and all-cause mortality was compared for an equal period of 24 months 'before' (Epoch 1) and 'after' (Epoch 2) RPS with Bifidobacterium breve M-16V in neonates <34 weeks. Multivariate logistic regression analysis was conducted to adjust for relevant confounders.
resultsA total of 1755 neonates (Epoch I vs. II: 835 vs. 920) with comparable gestation and birth weights were admitted. There was a significant reduction in NEC ≥ Stage II: 3% vs. 1%, adjusted odds ratio (aOR) = 0.43 (95%CI: 0.21-0.87); 'NEC ≥ Stage II or all-cause mortality': 9% vs. 5%, aOR = 0.53 (95%CI: 0.32-0.88); but not all-cause mortality alone: 7% vs. 4%, aOR = 0.58 (95% CI: 0.31-1.06) in Epoch II. The benefits in neonates <28 weeks did not reach statistical significance: NEC ≥ Stage II: 6% vs. 3%, aOR 0.51 (95%CI: 0.20-1.27), 'NEC ≥ Stage II or all-cause mortality', 21% vs. 14%, aOR = 0.59 (95%CI: 0.29-1.18); all-cause mortality: 17% vs. 11%, aOR = 0.63 (95%CI: 0.28-1.41). There was no probiotic sepsis.
conclusionRPS with Bifidobacterium breve M-16V was associated with decreased NEC≥ Stage II and 'NEC≥ Stage II or all-cause mortality' in neonates <34 weeks. Large sample size is required to assess the potential benefits of RPS in neonates <28 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.